GlassScriptPhysician profile
Ann C Lentz
NPI 1053757336
$6,523.85
in general payments reported to CMS, 2019-2025
30 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $791 · 2022: $1,064 · 2023: $1,206 · 2024: $1,577 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,572 · Education: $96.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,572.45 |
| Education | $96.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,051.74 | 2021-2025 | Evenity, Tavneos, Otezla |
| Abbvie INC. | $1,037.47 | 2021-2025 | |
| Pfizer INC. | $552.83 | 2021-2025 | |
| Janssen Biotech, INC. | $525.70 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $427.99 | 2021-2025 | |
| Ucb, INC. | $411.78 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $301.77 | 2021-2024 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $295.76 | 2022-2025 | Acthar |
| Radius Health, INC. | $230.26 | 2022-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $214.59 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $179.93 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $172.69 | 2021-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $129.42 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $126.08 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $117.93 | 2023-2025 | Actemra, Gazyva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $110.26 | 2023-2025 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $96.07 | 2023-2025 | Lupkynis |
| Organon LLC | $95.33 | 2023-2025 | Renflexis, Hadlima, Nexplanon |
| Fresenius Kabi USA, LLC | $95.29 | 2024-2025 | Idacio |
| Kiniksa Pharmaceuticals, LTD. | $64.77 | 2021-2023 | Arcalyst |
| Tersera Therapeutics LLC | $54.33 | 2022-2024 | Quzyttir |
| Boston Scientific Corporation | $43.50 | 2025 | Watchman Flx |
| Mylan Institutional INC. | $25.43 | 2023 | Hulio |
| Teva Pharmaceuticals USA, INC. | $25.08 | 2025 | Simlandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2025 | Ofev |
| Celltrion USA INC. | $24.50 | 2023 | Yuflyma |
| Biocon Biologics INC | $23.83 | 2024 | Hulio |
| Pacira Pharmaceuticals Incorporated | $22.21 | 2023 | Zilretta, Iovera |
| Kyowa Kirin, INC. | $21.64 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.94 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Lentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.